The newly formed San Diego cancer drugmaker Seragon Pharmaceuticals Inc. has appointed Debasish Roychowdhury as its new acting chief medical officer.

Roychowdhury has a depth of experience in research and development, having worked in leadership roles at Sanofi SA, GlaxoSmithKline PLC and Eli Lilly & Co. Most recently, he led the global oncology division at Sanofi from August 2009 to September 2013.

Seragon was spun off last August from Aragon Pharmaceuticals Inc., which was bought by Johnson & Johnson (NYSE: JNJ) in a deal worth up to $1 billion. Seragon raised $30 million in Series A financing in October, largely from the same investor group that founded Aragon.